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Following publication of the original article \[[@CR1]\], the author reported that Tables [3](#Tab1){ref-type="table"} and [4](#Tab2){ref-type="table"} were incorrect due to a production error. Table 3Effect of cisplatin (CP) and different treatments of AHE on lung tissue antioxidant enzymesGroupPOD\
(U/min)SOD\
(U/mg protein)CAT\
(U/min)QR\
(nM/min/mg protein)Control9.56 ± 0.635^b^1.366 ± 0.038^b^18.48 ± 0.058^b^128.2 ± 0.81^b^CP5.03 ± 0.271^a^0.765 ± 0.019^a^10.83 ± 0.049^a^83.99 ± 0.486^a^AHE alone10.29 ± 0.314^b^1.358 ± 0.058^b^18.57 ± 0.057^b^128.9 ± 0.179^b^CP + AHE6.22 ± 0.128^a,\ d^0.982 ± 0.035^a,b\*,d\*\*^14.15 ± 0.083^a,b,\ d^98.82 ± 1.232^a.b,\ d^AHE + CP9.18 ± 0.185^b,\ c^1.255 ± 0.038^b,c\*\*^17.07 ± 0.026^a,b,\ c^119.5 ± 1.283^a,b,\ c^CP + Sily9.20 ± 0.208^b^1.262 ± 0.021^b^17.14 ± 0.081^a^,^b^119.9 ± 1.008^a,b^Values expressed as mean ± SEM. ^a^ Significance at *p* \< 0.0001 Vs. control group, ^b^ Significance at *p* \< 0.0001 Vs. Cisplatin (CP) group. ^c^ Significance at *p* \< 0.0001 of AHE + CP pre-treated group Vs. CP + AHE post-treated group. ^d^ Significance at *p* \< 0.0001 of CP + AHE treatment groups Vs CP + Sily group. ^\*^, ^\*\*^: Significant difference at *p* \< 0.001. Non-significant difference (*p* \> 0.05) was recorded between control and AHE alone treated group in all parameters (One way ANOVA followed by Tukey's multiple comparison tests) Table 4Effect of cisplatin (CP) and different treatments of AHE on lungs tissue antioxidant enzymes and GSH profileGroupGSH\
(μM/g tissue)GR\
(nM/min/mg protein)GST\
(nM/min/mg protein)γ-GT\
(nM/min/mg Protein)GPx\
(nM/min/mg Protein)Control16.12 ± 0.578^b^143.7 ± 1.342^b^98.85 ± 0.918^b^295.4 ± 1.113^b^107.4 ± 0.730^b^CP8.334 ± 0.356^a^98.02 ± 0.619^a^68.17 ± 0.962^a^82.82 ± 0.958^a^54.08 ± 0.909^a^AHE alone6.38 ± 0.207^b^144.0 ± 1.492^b^99.79 ± 1.865 ^b^295.6 ± 0.599^b^108.8 ± 1.216^b^CP + AHE11.99 ± 0.305^a,b,\ d^116.9 ± 0.813^a,b,d^78.34 ± 1.076^a,b\*\*,d\*\*^137.8 ± 1.017^a,b,d^71.28.8 ± 0.501^a,b,c^AHE + CP15.63 ± 0.532^b,\ c^135.0 ± 0.393 ^a,b,c^89.65 ± 1.49 ^a\*\*,b,c^261.4 ± 0.802^a,b,c^92.78 ± 1.216^a,b,c^CP + Sily15.29 ± 0.312^b^133.8 ± 1.25 ^a,b^87.60 ± 1.644^a,b^264.3 ± 1.067^a,b^95.64 ± 1.573^a,b^Values expressed as mean ± SEM. ^a^ Significance at *p* \< 0.0001 Vs. control group, ^b^ Significance at *p* \< 0.0001 Vs. Cisplatin (CP) group. ^c^ Significance at *p* \< 0.0001 of AHE + CP pre-treated group Vs. CP + AHE post-treated group. ^d^ Significance at *p* \< 0.0001 of CP + AHE treatment groups Vs CP + Sily group. ^\*^, ^\*\*^: Significant difference at *p* \< 0.001. Non-significant difference (*p* \> 0.05) was recorded between control and AHE alone treated group in all parameters (One way ANOVA followed by Tukey's multiple comparison tests)

The corrected tables are given below.
